Anti-Major Depressive Disorder Raw Materials Agomelatine 138112-76-2

Model NO.
TGY022023043003
Shelf Life
2 Years
Grade
Pharmaceuticals Grade
Shipping Time
Within 3-7 Working Days
Storage
Cool Dry Place
Specificcation
99%
CAS No.
138112-76-2
Product Name
Agomelatine
Appearance
White to Powder
Transport Package
Foil Bag, Box, Drum
Specification
99% min
Trademark
TGY
Origin
China
HS Code
3001200010
Production Capacity
1500kg/Month
Reference Price
$ 1.80 - 5.40

Product Description


Anti-Major Depressive Disorder Raw Materials Agomelatine 138112-76-2
Anti-Major Depressive Disorder Raw Materials Agomelatine 138112-76-2

Product Name:AGOMELATINE

Synonyms:AGOMELATINE;n-(2-(7-methoxy-1-naphthalenyl)ethyl)-acetamid;n-(2-(7-methoxy-1-naphthalenyl)ethyl)acetamide;n-(2-(7-methoxynaphth-1-yl)ethyl)acetamide;S20098,N-[2-(7-Methoxynaphth-1-yl)ethyl]acetamide;S 20098;AGOMELATIN;Acetamide, N-(2-(7-methoxy-1-naphthalenyl)ethyl)-

CAS:138112-76-2

MF:C15H17NO2

MW:243.30098

Product Categories:Aromatics Compounds;Aromatics;Neurochemicals;APIS;API;Agomelatine;Valdoxan, Melitor, Thymanax

mp :107-109°C

storage temp. :-20°C Freezer

Chemical Properties:White powder

Usage:Agomelatine is an antidepressant drug. It is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor. Activation of 5-HT2C receptors by serotonin inhibits dopamine and norepinephrine release. 


Anti-Major Depressive Disorder Raw Materials Agomelatine 138112-76-2

Agomelatine is indicated for the treatment of major depressive episodes in adults.Ten placebo controlled trials have been performed to investigate the short term efficacy of agomelatine in major depressive disorder. At the end of treatment, significant efficacy was demonstrated in six of the ten short-term double-blind placebo-controlled studies.Two were considered "failed" trials, as comparators of established efficacy failed to differentiate from placebo. Efficacy was also observed in more severely depressed patients in all positive placebo-controlled studies.The maintenance of antidepressant efficacy was demonstrated in a relapse prevention study .


Anti-Major Depressive Disorder Raw Materials Agomelatine 138112-76-2

 

GOUV.NE, 2023